Cerebrospinal fluid phospho-tau, total tau and beta-amyloid(1-42) in the differentiation between Alzheimer's disease and vascular dementia
(2002) In Dementia and Geriatric Cognitive Disorders 14(4). p.183-190- Abstract
- The two most frequently examined biomarkers in the diagnosis of dementia are cerebrospinal fluid (CSF) tau and beta-amyloid(1-42) (Abeta(1-42)). An assay for tau phosphorylated at threonine 181 (phospho-tau) has recently been developed. We studied these three markers in patients with possible Alzheimer's disease (AD; n = 23), probable AD (n = 50), AD with relevant cerebrovascular disease (AD with CVD; n = 14), possible vascular dementia (VaD; n = 39), probable VaD (n = 36), cognitively impaired (n = 13) and 27 neurologically healthy controls. Compared with the controls, tau levels were significantly increased in possible AD, probable AD, AD with CVD and probable VaD. Abeta(1-42) was decreased in all dementia groups compared with the... (More)
- The two most frequently examined biomarkers in the diagnosis of dementia are cerebrospinal fluid (CSF) tau and beta-amyloid(1-42) (Abeta(1-42)). An assay for tau phosphorylated at threonine 181 (phospho-tau) has recently been developed. We studied these three markers in patients with possible Alzheimer's disease (AD; n = 23), probable AD (n = 50), AD with relevant cerebrovascular disease (AD with CVD; n = 14), possible vascular dementia (VaD; n = 39), probable VaD (n = 36), cognitively impaired (n = 13) and 27 neurologically healthy controls. Compared with the controls, tau levels were significantly increased in possible AD, probable AD, AD with CVD and probable VaD. Abeta(1-42) was decreased in all dementia groups compared with the controls. In contrast, phospho-tau levels were increased only in probable AD compared with the controls. From the results of the present study, it is concluded that neither measurement of phospho-tau, tau nor Abeta(1-42) in CSF can discriminate entirely between dementia and cognitively non-disturbed controls or between dementia of different aetiologies in the clinical diagnostic procedure. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1297542
- author
- Nägga, Katarina LU ; Gottfries, Johan ; Blennow, Kaj and Marcusson, Jan
- publishing date
- 2002
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Dementia and Geriatric Cognitive Disorders
- volume
- 14
- issue
- 4
- pages
- 183 - 190
- publisher
- Karger
- external identifiers
-
- wos:000179464900003
- scopus:0036968010
- ISSN
- 1420-8008
- DOI
- 10.1159/000066023
- language
- English
- LU publication?
- no
- id
- d251df4a-8156-4788-b611-a19ef94dd4e8 (old id 1297542)
- date added to LUP
- 2016-04-01 12:17:25
- date last changed
- 2022-02-03 20:12:30
@article{d251df4a-8156-4788-b611-a19ef94dd4e8, abstract = {{The two most frequently examined biomarkers in the diagnosis of dementia are cerebrospinal fluid (CSF) tau and beta-amyloid(1-42) (Abeta(1-42)). An assay for tau phosphorylated at threonine 181 (phospho-tau) has recently been developed. We studied these three markers in patients with possible Alzheimer's disease (AD; n = 23), probable AD (n = 50), AD with relevant cerebrovascular disease (AD with CVD; n = 14), possible vascular dementia (VaD; n = 39), probable VaD (n = 36), cognitively impaired (n = 13) and 27 neurologically healthy controls. Compared with the controls, tau levels were significantly increased in possible AD, probable AD, AD with CVD and probable VaD. Abeta(1-42) was decreased in all dementia groups compared with the controls. In contrast, phospho-tau levels were increased only in probable AD compared with the controls. From the results of the present study, it is concluded that neither measurement of phospho-tau, tau nor Abeta(1-42) in CSF can discriminate entirely between dementia and cognitively non-disturbed controls or between dementia of different aetiologies in the clinical diagnostic procedure.}}, author = {{Nägga, Katarina and Gottfries, Johan and Blennow, Kaj and Marcusson, Jan}}, issn = {{1420-8008}}, language = {{eng}}, number = {{4}}, pages = {{183--190}}, publisher = {{Karger}}, series = {{Dementia and Geriatric Cognitive Disorders}}, title = {{Cerebrospinal fluid phospho-tau, total tau and beta-amyloid(1-42) in the differentiation between Alzheimer's disease and vascular dementia}}, url = {{http://dx.doi.org/10.1159/000066023}}, doi = {{10.1159/000066023}}, volume = {{14}}, year = {{2002}}, }